Organovo Holdings, Inc. (NASDAQ:ONVO) Shares Sold by Prescott Group Capital Management L.L.C.

Prescott Group Capital Management L.L.C. reduced its position in shares of Organovo Holdings, Inc. (NASDAQ:ONVO) by 32.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 280,511 shares of the medical research company’s stock after selling 133,524 shares during the period. Prescott Group Capital Management L.L.C. owned approximately 1.83% of Organovo worth $129,000 at the end of the most recent quarter.

Organovo Stock Performance

Organovo stock opened at $0.52 on Friday. Organovo Holdings, Inc. has a 1 year low of $0.32 and a 1 year high of $1.83. The firm’s 50 day moving average price is $0.44 and its two-hundred day moving average price is $0.45. The firm has a market cap of $8.89 million, a price-to-earnings ratio of -0.61 and a beta of 0.44.

Organovo (NASDAQ:ONVO) last issued its earnings results on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.05 million. As a group, equities analysts predict that Organovo Holdings, Inc. will post -0.77 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Organovo in a research report on Monday. They set a “sell” rating for the company.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.